All In MedTech

Device Trial Radar · NCT07927166

Local Antibiotic Delivery From an Intramedullary Nail After Surgical Treatment of Tibial Fractures at High Risk of Infection

Local Antibiotic Delivery From an Intramedullary Nail After Surgical Treatment of Tibial Fractures at High Risk of Infection: A Multicenter, Prospective, Open-Label Clinical Trial (RESELUTE Study)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

317

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Feb 2029

Study completion Feb 2030

Sponsor

Lead sponsor
Reselute, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Major Extremity Trauma Research Consortium
First posted
Nov 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether an antibiotic-releasing nail placed inside the shinbone (tibia) helps prevent infection and supports bone healing in adults with an open shinbone fracture. The study will test two versions of the Reselution Tibial Intramedullary Fixation System: one that releases vancomycin (Reselution V) and one that releases vancomycin and tobramycin (Reselution VT). The main question it aims to answer is: within 12 months of surgery, how many participants heal without unplanned repeat surgery on the injured leg, have a healed bone on X-ray, and have no serious device-related side effects? Participants will: * Have surgery to fix their shinbone with the Reselution nail * Have blood tests in the first 2 weeks after surgery (this testing may be stopped for later participants after an independent safety review) * Attend follow-up visits for up to 24 months, including X-rays and questionnaires

Conditions

  • Tibial Fractures
  • Fractures, Open

Interventions

  • Reselution V Tibial Intramedullary Fixation SystemDevice

    Device-led combination product: titanium tibial intramedullary nail with an internal core loaded with vancomycin for local sustained antibiotic delivery.

  • Reselution VT Tibial Intramedullary Fixation SystemDevice

    Device-led combination product: titanium tibial intramedullary nail with an internal core loaded with vancomycin and tobramycin for local sustained antibiotic delivery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Composite Success at 12 MonthsTime frame: 12 months after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland, Baltimore

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.